14 results about "Erythrogenin" patented technology

To provide a novel erythropoietin production promoter.SOLUTION: An erythropoietin production promoter contains isorhamnetin and / or an isorhamnetin glycoside as an active ingredient.SELECTED DRAWING: Figure 1

The present invention relates to the use of ligustrazine nitrone derivatives and pharmaceutical composition thereof for the treatment and prevention of diseases of diabetic complications, which include renal anemia. The ligustrazine nitrone derivatives have the structure of the general formula (I).Experimental results indicated that the ligustrazine nitrone derivatives can significantly increase the levels of serum iron and erythropoietin in STZ induced SD rats and spontaneously hypertensive rats, and can be used for treating and preventing renal anemia caused by decrease in renal EPO production and / or concomitant iron deficiency. Therefore, the ligustrazine nitrone derivatives can be made into various dosage forms with a drug carrier. The derivatives can be prepared into various dose forms together with drug carriers.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and / or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

A method of producing renal interstitial progenitor cells, the method including the step of culturing HOXC10-positive cells in a medium comprising a GSK (glycogen synthase kinase)-3β inhibitor, a SHH (Sonic Hedgehog) signal activator, and a TGF (transforming growth factor) β inhibitor, and preferably also comprising IL (interleukin)-1β and retinoic acid, to induce the renal interstitial progenitor cells.

The invention discloses a chlamydomonas reinhardtii source organism iron steady state regulator and application thereof, and belongs to the technical field of biology. The chlamydomonas reinhardtii hydroxyproline-rich glycoprotein or the protein component thereof disclosed by the invention can activate low-oxygen inducible factor signal channels of intestinal tracts, livers and kidneys, and up-regulate the expression of iron absorption transporters such as a divalent metal ion carrier 1, duodenum cytochrome b, membrane iron transporters and ferrous oxidase in intestinal epithelial cells; according to the present invention, the liver hepcidin overexpression caused by inflammation can be inhibited, the generation of erythropoietin in the liver and the kidney can be promoted so as to stimulate the absorption of the body on the iron nutrient, and the compound can be used in the anemia improving health food and the anemia improving drug. The organism iron homeostasis regulator adopted by the invention is derived from microalgae food, so that compared with a conventional artificially synthesized organism iron homeostasis regulator drug, the organism iron homeostasis regulator has the advantage of no toxic or side effect.

The invention relates to negative functional modulators of at least one variant of the non-erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA.Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation.The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent.According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described.According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and / or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

The present invention relates to a new variant of EPO. In this study, the inventors identified a particular EPO differing from kidney-type EPO due to a different glycosylation pattern in patients with different diseases (for example idiopathic erythrocytosis, liver / kidney disorder, tumors...). This new EPO is similar to pre-term newborn EPO produced by the liver that differs from the normal EPO produced from renal interstitial cells due to different post-translational modifications (glycosylations). This new EPO shows an increased biological activity via activation of the EPO receptor (EPOR), that can explain the origin of erythrocytosis. The detection of this specific liver-like EPO could be used as a diagnostic tool to better adapt and follow the treatments of erythrocytosis patients or in other diseases associated with the overproduction of red blood cells. Thus, the invention relates to a specific EPO protein which differs from the EPO with kidney-type glycosylation pattern.

The invention provides a preparation method of erythropoietin protein, a signal peptide-8 * His-SEU1 gene and application, and belongs to the technical field of erythropoietin protein preparation. The signal peptide-8 * His-SEU1 gene is formed by connecting a signal peptide, an 8 * His tag and an SEU1 tag in series, and the amino acid sequence of the signal peptide is as shown in SEQ ID NO. 2. According to the research, the signal peptide-8 * His-SEU1 gene is utilized, so that the signal peptide-8 * His-SEU1 gene cannot be cut in an erythropoietin protein expression process and is not influenced by eukaryotic cell endogenous enzyme, and stable expression and purification of hEPO (human erythropoietin) are ensured. In combination with a eukaryotic host cell culture system, the hEPO protein can be secreted out of cells, and the purity of the hEPO protein is remarkably improved.

The present invention relates to long-acting erythropoietin (EPO), an EPO mimetic peptide, and a use of the EPO.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

The present invention relates to a method for producing erythrocytes, and more specifically, to a method comprising the steps of: (S1) culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells; (S2) obtaining a CD41- / CD34-cell population from the cell culture medium; and (S3) maturing the obtained cell population in a first medium containing erythropoietin, and thus high-quality erythrocytes can be produced in a short time.

The invention features polypeptides that include an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

The present invention relates to the fields of biotechnology and medicine and describes pharmaceutical compositions of recombinant human erythropoietin characterized by a microheterogeneity of fucosylated N-glycans formed by di-, tri-, and tetra-antennary structures with mono- and bi-sialylated sialic acid residues representing 40-60% of total glycans, tri-sialylated sialic acid residues representing 40-43% of total glycans, and tetra-sialylated sialic acid residues representing 10-13% of total glycans. This glycosylation pattern confers properties that allow the composition to be used in disorders of the nervous system. Methods for obtaining the pharmaceutical compositions described herein are also described.